Does Express Scripts Cover Wegovy? Insurance Guide 2026

Obesity and type 2 diabetes remain leading health challenges in the U.S., with over 40% of adults classified as obese and 37 million living with diabetes. Wegovy, a once-weekly injectable medication containing semaglutide, has emerged as a groundbreaking treatment for both conditions. Approved by the FDA for chronic weight management and diabetes, Wegovy has shown remarkable efficacy in clinical trials, helping patients achieve significant and sustained weight loss. However, its high cost—often exceeding $1,300 per month without insurance—makes coverage a critical concern. For millions of Americans enrolled in Express Scripts pharmacy benefit plans, understanding whether and how Wegovy is covered can mean the difference between access and financial strain. This guide provides an evidence-based breakdown of Wegovy coverage through Express Scripts in 2026, including eligibility, costs, prior authorization, and steps to take if denied.

Does Express Scripts Cover Wegovy for Diabetes?

Express Scripts, one of the nation’s largest pharmacy benefit managers (PBMs), generally covers Wegovy for patients with type 2 diabetes under specific conditions. As of 2026, Wegovy is recognized by Express Scripts as a medically necessary treatment for glycemic control in adults with type 2 diabetes who have not achieved target A1C levels with oral medications or other injectables like insulin. Coverage is typically aligned with FDA labeling, which approves Wegovy (semaglutide 2.4 mg) for diabetes management when used alongside diet and exercise.

However, coverage is not automatic. Express Scripts requires prior authorization to confirm that Wegovy is being prescribed for diabetes, not solely for weight loss. The PBM’s clinical criteria often include documentation of an A1C ≥ 7.0% despite prior therapy, a body mass index (BMI) ≥ 27 kg/m² with weight-related comorbidities, or intolerance to other diabetes medications. Evidence from the SUSTAIN clinical trials supports Wegovy’s efficacy in reducing A1C by 1.5–1.8 percentage points, making it a strong candidate for coverage when other treatments fail.

Patients should work with their healthcare providers to submit comprehensive medical records, including lab results and prior treatment history, to meet Express Scripts’ requirements for Wegovy coverage in diabetes management.

Does Express Scripts Cover Wegovy for Weight Loss?

Express Scripts does cover Wegovy for chronic weight management, but coverage is more restrictive than for diabetes. As of 2026, Wegovy is included in Express Scripts’ formulary for obesity treatment, but only for patients who meet strict clinical criteria. To qualify, patients must have a BMI ≥ 30 kg/m² or a BMI ≥ 27 kg/m² with at least one weight-related comorbidity, such as hypertension, dyslipidemia, or obstructive sleep apnea. These criteria align with the FDA’s approval of Wegovy for obesity and reflect evidence from the STEP clinical trials, which demonstrated an average weight loss of 15–17% over 68 weeks.

Despite these guidelines, Express Scripts often requires prior authorization to ensure Wegovy is medically necessary. The PBM may also mandate participation in a structured lifestyle intervention program, such as a diet and exercise plan, before approving coverage. Additionally, Express Scripts may limit coverage to a specific duration (e.g., 12–24 months) or require proof of weight loss progress to continue reimbursement. Patients should be prepared to provide documentation from their healthcare provider, including BMI calculations, medical history, and prior weight loss attempts, to secure coverage for Wegovy under Express Scripts.

How Much Does Wegovy Cost With Express Scripts?

The cost of Wegovy with Express Scripts varies significantly depending on the patient’s insurance plan, copay tier, and whether prior authorization is approved. Without insurance, Wegovy retails for approximately $1,300–$1,600 per month, but Express Scripts’ negotiated rates often reduce this cost for covered patients. For those with commercial insurance through Express Scripts, the out-of-pocket expense typically ranges from $25 to $250 per month, depending on the plan’s formulary tier. High-deductible health plans may require patients to pay the full negotiated price until their deductible is met, which can delay access to Wegovy.

Medicare and Medicaid coverage for Wegovy is more complex. While Medicare Part D does not cover Wegovy for weight loss due to federal restrictions on obesity medications, it may cover the drug for diabetes management. Medicaid coverage varies by state, with some programs covering Wegovy under prior authorization. Patients should contact Express Scripts or their insurance provider to confirm their specific copay or coinsurance for Wegovy, as well as any annual or lifetime maximums on coverage.

For those facing high costs, Novo Nordisk, the manufacturer of Wegovy, offers a savings card that can reduce out-of-pocket expenses to as little as $0–$25 per month for eligible commercially insured patients. However, this program is not available to Medicare or Medicaid beneficiaries.

Wegovy Prior Authorization for Express Scripts

Prior authorization is a standard requirement for Wegovy coverage under Express Scripts, designed to ensure the medication is prescribed appropriately and cost-effectively. The process involves the healthcare provider submitting clinical documentation to demonstrate that the patient meets Express Scripts’ criteria for Wegovy use. For diabetes, this includes proof of an A1C ≥ 7.0% despite prior therapy, while for weight loss, it requires a BMI ≥ 30 kg/m² or ≥ 27 kg/m² with comorbidities, along with evidence of failed weight loss attempts through diet and exercise.

Express Scripts’ prior authorization review typically takes 3–10 business days, during which the PBM evaluates the patient’s medical history, lab results, and treatment plan. If the request is denied, Express Scripts provides a reason, such as insufficient documentation or failure to meet clinical criteria. Patients and providers can appeal the decision by submitting additional evidence, such as records of prior weight loss attempts or comorbid conditions like hypertension or sleep apnea.

To streamline the process, providers should use Express Scripts’ online portal or fax the required forms, including the prior authorization request and supporting medical records. Delays or denials can often be avoided by ensuring all criteria are met and documentation is thorough. Patients are encouraged to follow up with their provider and Express Scripts to track the status of their Wegovy prior authorization.

How to Get Express Scripts to Cover Wegovy

Securing coverage for Wegovy through Express Scripts requires a proactive and collaborative approach between patients and their healthcare providers. The first step is confirming eligibility by reviewing Express Scripts’ clinical criteria for Wegovy, which vary for diabetes and weight loss. For diabetes, patients must demonstrate inadequate glycemic control with prior therapies, while for weight loss, they must meet BMI thresholds and have documented weight-related comorbidities.

Once eligibility is confirmed, the healthcare provider must submit a prior authorization request to Express Scripts, including comprehensive medical records. This documentation should highlight the patient’s treatment history, lab results (e.g., A1C levels for diabetes), BMI calculations, and prior weight loss attempts. Evidence from clinical trials, such as the SUSTAIN and STEP studies, can strengthen the case for Wegovy by demonstrating its efficacy in improving glycemic control and promoting weight loss.

If the initial request is denied, patients and providers can appeal the decision by submitting additional evidence or requesting a peer-to-peer review with an Express Scripts clinical pharmacist. Persistence is key, as appeals often succeed when new or overlooked information is provided. Patients should also explore manufacturer savings programs, such as Novo Nordisk’s Wegovy savings card, which can reduce out-of-pocket costs for eligible patients while coverage is being pursued.

What to Do If Express Scripts Denies Wegovy

If Express Scripts denies coverage for Wegovy, patients have several options to challenge the decision and potentially secure access to the medication. The first step is to request a detailed explanation of the denial from Express Scripts, which will outline the specific reasons, such as failure to meet clinical criteria or insufficient documentation. This information is critical for crafting an effective appeal.

Patients and their healthcare providers should gather additional evidence to address the denial reasons. For example, if the denial cites a lack of prior weight loss attempts, providers can submit records of diet, exercise, or previous weight loss medications. If the denial is based on BMI thresholds, updated measurements or documentation of comorbidities (e.g., hypertension, sleep apnea) can strengthen the case. Appeals should be submitted in writing, along with any new evidence, and may include a letter of medical necessity from the provider.

If the appeal is denied, patients can request an external review by an independent third party, as mandated by the Affordable Care Act. This process is available for most commercial insurance plans and can overturn Express Scripts’ decision if the reviewer determines that Wegovy is medically necessary. Patients should also explore alternative funding options, such as Novo Nordisk’s patient assistance program or clinical trials, while pursuing the appeal.

Express Scripts Alternatives If Wegovy Is Not Covered

If Wegovy is not covered by Express Scripts or remains unaffordable, patients have several alternatives to explore for diabetes management or weight loss. For diabetes, other GLP-1 receptor agonists, such as Ozempic (semaglutide) or Trulicity (dulaglutide), may be covered by Express Scripts and offer similar glycemic benefits. These medications are often preferred by PBMs due to lower costs or broader formulary inclusion. Patients should consult their healthcare provider to determine if an alternative GLP-1 agonist is appropriate.

For weight loss, other FDA-approved medications, such as Saxenda (liraglutide), Qsymia (phentermine/topiramate), or Contrave (naltrexone/bupropion), may be covered by Express Scripts. While these medications have different mechanisms of action and efficacy profiles, they can provide meaningful weight loss for eligible patients. Lifestyle interventions, such as structured diet and exercise programs, remain a cornerstone of weight management and may be required by Express Scripts before approving any weight loss medication.

Patients can also explore manufacturer savings programs, such as Novo Nordisk’s Wegovy savings card or patient assistance programs, which provide financial support for eligible individuals. Clinical trials for new weight loss or diabetes medications may offer access to cutting-edge treatments at no cost. Finally, patients should discuss all options with their healthcare provider to develop a personalized plan that aligns with their health goals and insurance coverage.

Frequently Asked Questions

Does Express Scripts cover Wegovy for weight loss?

Yes, Express Scripts covers Wegovy for weight loss, but only for patients who meet specific clinical criteria, including a BMI ≥ 30 kg/m² or ≥ 27 kg/m² with weight-related comorbidities. Prior authorization is typically required, and coverage may be limited to patients who have failed prior weight loss attempts through diet and exercise. Patients should work with their healthcare provider to submit the necessary documentation for approval.

How much is the Wegovy copay with Express Scripts?

The copay for Wegovy with Express Scripts varies depending on the patient’s insurance plan and formulary tier. For commercially insured patients, copays typically range from $25 to $250 per month, while those with high-deductible plans may pay the full negotiated price until their deductible is met. Medicare and Medicaid coverage varies, with some state Medicaid programs covering Wegovy under prior authorization.

Can I appeal if Express Scripts denies Wegovy?

Yes, patients can appeal a denial of Wegovy coverage by Express Scripts. The appeal process involves submitting additional medical documentation or requesting a peer-to-peer review with an Express Scripts clinical pharmacist. If the appeal is denied, patients can request an external review by an independent third party, which may overturn the decision if Wegovy is deemed medically necessary.

Disclaimer from HealthLeague Medical Board: This article is for informational purposes only and does not constitute medical or insurance advice. Coverage for Wegovy through Express Scripts is subject to individual plan terms, clinical criteria, and prior authorization requirements. Patients should consult their healthcare provider and insurance plan to confirm eligibility and coverage details. HealthLeague Medical Board does not endorse or guarantee coverage for any specific medication or treatment.